Handa Pharmaceuticals, Inc.
6620
Rank in Stocks
#11087
Handa Pharmaceuticals, Inc. operates as a specialized drug company,... Handa Pharmaceuticals, Inc. operates as a specialized drug company, concentrating its efforts on creating and advancing new medications for diverse health issues across both the United States and China. The firm currently offers Quetiapine XR, a treatment for Schizophrenia, as well as Dexlansoprazole DR capsules. Beyond its existing portfolio, Handa is actively cultivating a robust pipeline of therapies. This includes their cutting-edge ONCORE drug delivery platform, engineered to boost patient adherence and improve the safety of tyrosine kinase inhibitor oncology drugs. Other significant projects encompass a 505(b)(2)NDA therapeutic agent, Tascenso ODT for managing multiple sclerosis, and the oncology candidates HND-033 and HND-027. Furthermore, the company's development initiatives feature HND-004, designed for diabetic patients; HND-032, intended to aid in smoking cessation; and HND-026, a gastrointestinal medication. Founded in 2014, Handa Pharmaceuticals, Inc. has its main corporate headquarters situated in Tainan City, Taiwan.
Share Price
$3.75
Last synced: 2026-11-10
Market Cap
$609.42M
Change (1 day)
7.42%
Change (1 year)
-4.09%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Handa Pharmaceuticals, Inc. (6620)
Category
Healthcare
EPS for Handa Pharmaceuticals, Inc. (6620)
EPS as of June 2026 TTM: $0.10
According to Handa Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $0.10. At the end of 2025 the company had an EPS of $0.15, an increase over its 2024 EPS of $0.10.
EPS history for Handa Pharmaceuticals, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.10 | -36.60% |
| 2025 | $0.15 | 50.44% |
| 2024 | $0.10 | -41.75% |
| 2023 | $0.18 | -1,795.19% |
| 2022 | $-0.01 | -86.08% |
| 2021 | $-0.07 | -11.49% |
| 2020 | $-0.08 | 59.85% |
| 2019 | $-0.05 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | 6,736.38% |
DE
|
|
| $6.08 | 6,290.75% |
DE
|
|
| $1.55 | 1,530.49% |
JP
|
|
| $3.66 | 3,748.58% |
CH
|
|
| $0.45 | 373.19% |
IL
|
Questions about Handa Pharmaceuticals, Inc.'s earnings per share (EPS)
What is Handa Pharmaceuticals, Inc.'s earnings per share (EPS)?
Handa Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $0.10, as of Jun 2026.
What was Handa Pharmaceuticals, Inc.'s earnings per share (EPS) in 2025?
In 2025, Handa Pharmaceuticals, Inc.'s earnings per share (EPS) was $0.15, 50.00% more than in 2024 ($0.10).
How has Handa Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Handa Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2023 ($0.18) and lowest in 2020 ($-0.08).
How does Handa Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
Handa Pharmaceuticals, Inc.'s earnings per share (EPS) ($0.10) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.